Patient Risk Stratification Market Report 2026

The patient risk stratification market size has grown exponentially in recent years. It will grow from $2.81 billion in 2025 to $3.68 billion in 2026 at a compound annual growth rate (CAGR) of 31%. The growth in the historic period can be attributed to manual patient risk assessments, reliance on historical patient data, fragmented healthcare information systems, limited use of predictive analytics, lack of standardized risk models.

The patient risk stratification market size is expected to see exponential growth in the next few years. It will grow to $10.64 billion in 2030 at a compound annual growth rate (CAGR) of 30.4%. The growth in the forecast period can be attributed to integration of machine learning and ai in risk stratification, increasing adoption among healthcare providers and payers, growth of cloud-based risk stratification solutions, rising demand for real-time clinical decision support, expansion of population health management initiatives. Major trends in the forecast period include increasing adoption of ai-based risk prediction models, rising deployment of cloud-based risk stratification platforms, growing integration of risk stratification with clinical workflows, increasing focus on real-time patient risk monitoring, rising utilization of data analytics for population health management.

The increasing burden of chronic diseases is expected to drive growth in the patient risk stratification market in the coming years. Chronic diseases are long-term health conditions that typically persist for three months or longer. Factors contributing to the rising burden include an aging population, unhealthy lifestyles, urbanization, environmental influences, limited healthcare access, economic disparities, and higher stress levels. Patient risk stratification enables the identification of individuals at varying risk levels for chronic diseases, supporting personalized care, early intervention, better resource allocation, and improved health outcomes. For example, in June 2025, the World Health Organization (WHO), a Switzerland-based international specialized agency, reported that noncommunicable diseases (NCDs) remain the leading cause of death and disability worldwide, including in the WHO European Region, where 1 in 5 men and 1 in 10 women die before age 70 due to NCDs such as cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes. Therefore, the growing burden of chronic diseases is fueling the patient risk stratification market.

Key companies in the patient risk stratification market are advancing technological solutions, such as artificial intelligence (AI) in disease screening, to improve early detection, patient outcomes, and healthcare efficiency. AI-driven disease screening uses sophisticated algorithms and machine learning to analyze medical data, enabling early detection, more accurate diagnoses, and personalized treatment plans. For instance, in May 2024, WELL Health Technologies Corporation, a Canada-based healthcare company, and its investee HEALWELL AI, a Canadian firm focused on AI and data science for preventative care, launched WELL AI Decision Support (WAIDS). This platform, targeting rare diseases and chronic conditions such as kidney disease, hypertension, and diabetes, can detect over 100 diseases and provide risk stratification, helping clinicians identify care gaps and access actionable data at the point of care.

In December 2023, Healthcare Outcomes Performance Company (HOPCo), a US-based provider of healthcare performance improvement solutions, acquired MyACTome for an undisclosed amount. Through this acquisition, HOPCo aims to enhance patient outcomes and improve healthcare delivery efficiency. MyACTome is a US-based company offering a smartphone-based platform that specializes in assessing fall risk and frailty, playing a critical role in patient risk stratification.

Major companies operating in the patient risk stratification market are NextGen Healthcare Inc., Health Catalyst, Freenome, Strive Health, Medeanalytics Inc., Lightbeam Health Solutions, Graphnet Health Ltd., Equipo Health Inc., Epic Systems Corporation, Cerner Corporation, IBM Corporation, Allscripts Healthcare Solutions Inc., Medecision Inc., Cotiviti Inc., SAS Institute Inc., SCIO Health Analytics, Arcadia io, HealthEC LLC, Conifer Health Solutions LLC, Wellcentive Inc., ZeOmega Inc., LexisNexis Risk Solutions, Milliman Inc., NVision Health, RLDatix, Verisk Analytics Inc., Innovaccer Inc., eClinicalWorks, Enli Health Intelligence, Athenahealth Inc., i2i Population Health, 3M Health Information Systems, Change Healthcare, Cognizant Technology Solutions, McKesson Corporation, Evolent Health Inc.

North America was the largest region in the patient risk stratification market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient risk stratification market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the patient risk stratification market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the patient risk stratification market by increasing costs for imported software, cloud infrastructure, and analytics tools. Healthcare providers and payers in north america, europe, and asia-pacific are most affected due to dependency on global technology vendors. This may slow adoption and deployment of risk stratification solutions. However, tariffs also encourage regional software development, domestic cloud services, and enhanced compliance with local regulations, supporting long-term market resilience.

The patient risk stratification market research report is one of a series of new reports that provides patient risk stratification market statistics, including patient risk stratification industry global market size, regional shares, competitors with a patient risk stratification market share, detailed patient risk stratification market segments, market trends and opportunities, and any further data you may need to thrive in the patient risk stratification industry. This patient risk stratification market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Patient risk stratification is the process of evaluating and categorizing patients based on their likelihood of experiencing adverse health outcomes. It helps identify high-risk patients for targeted interventions, optimize resource use, support preventive care, improve care coordination, enhance patient outcomes, reduce costs, and facilitate population health management.

The primary types of patient risk stratification are predictive, retrospective, prospective, and concurrent models. Predictive models use historical and current patient data to forecast future health outcomes and identify individuals at high risk of developing specific conditions or complications. Key components include software and services, with delivery models available as on-premise or cloud-based solutions. Applications include risk adjustment, clinical workflow optimization, revenue cycle management, and more, and they are utilized by healthcare providers, payers, and other end users.

The patient risk stratification market includes revenues earned by entities by risk assessment and stratification services, telehealth services, medication management services, chronic disease risk assessment services, and genomic risk stratification services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.